Deepu Madduri, MD, on the Future Potential of Therapies to Treat Multiple Myeloma
The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.
In an interview with CancerNetwork®, Deepu Madduri, MD, assistant professor of Medicine (Hematology and Medical Oncology), associate director of Cellular Therapy Service, and director of Clinical Operations with the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and the Icahn School of Medicine at Mount Sinai, spoke about the research presented at the 62nd Annual ASH Meeting & Exposition that she found to be most exciting for the treatment of patients with multiple myeloma.
Transcription:
Some of the studies at ASH that I found really encouraging [were about] the Allogene [Therapeutics] CAR T[-cell therapy]. What was really encouraging about that was the time the patients were enrolled on the study and actually given Allogene was 5 days. I think in this heavily pretreated population, as we wait for the CAR T cells to be manufactured, we do see a lot of patients progressing, so this was something that was very encouraging.
There [are] also other trials, like the Genentech study [of a] bispecific [agent] as well as the GPRC5D from Janssen. These are interesting because they’re both targets that express on solely plasma cells. It’s really nice to see something in this space other than BCMA that we can use to target myeloma [in our] patients.
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
